Browsing by Author "Balaña, Carmen"

Sort by: Order: Results:

  • A comparison of RNA-Seq results from paired formalin-fixed paraffin-embedded and fresh-frozen glioblastoma tissue samples
    Esteve-Codina, Anna; Arpí Llucià, Oriol; Martínez-García, Maria; Pineda, Estela; Mallo, Mar; Gut, Marta; Carrato, Cristina; Rovira Guerín, Ana; Lopez, Raquel; Tortosa, Avelina; Dabad, Marc; del Barco, Sonia; Heath, Simon; Bagué, Silvia; Ribalta, Teresa; Alameda Quitllet, Francisco; de la Iglesia, Nuria; Balaña, Carmen; GLIOCAT Group (Public Library of Science (PLoS), 2017)
    The molecular classification of glioblastoma (GBM) based on gene expression might better explain outcome and response to treatment than clinical factors. Whole transcriptome sequencing using next-generation sequencing ...
  • Geometrical Measures Obtained from Pretreatment Postcontrast T1 Weighted MRIs Predict Survival Benefits from Bevacizumab in Glioblastoma Patients.
    Molina, David; Pérez-Beteta, Julián; Martínez-González, Alicia; Sepúlveda, Juan M.; Peralta, Sergi; Gil-Gil, Miguel J.; Reynes, Gaspar; Herrero, Ana; Peñas, Ramón De Las; Luque, Raquel; Capellades Font, Jaume; Balaña, Carmen; Pérez-García, Víctor M. (Public Library of Science (PLoS) , 2016)
    BACKGROUND: Antiangiogenic therapies for glioblastoma (GBM) such as bevacizumab (BVZ), have been unable to extend survival in large patient cohorts. However, a subset of patients having angiogenesis-dependent tumors might ...
  • Pseudoprogression as an adverse event of glioblastoma therapy
    Balaña, Carmen; Capellades Font, Jaume; Martínez-García, Maria; Alameda Quitllet, Francisco; GLIOCAT Group (Wiley, 2017)
    We explored predictive factors of pseudoprogression (PsP) and its impact on prognosis in a retrospective series of uniformly treated glioblastoma patients. Patients were classified as having PsP, early progression (eP) or ...

Search DSpace

Browse

My Account

In collaboration with Compliant to Partaking